Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | CNR2 | P34972 | 6/20 | 0.53 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.51 |
| ▸ | MMP2 | P08253 | 2/20 | 0.50 |
| ▸ | MMP9 | P14780 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.47 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL236526 | 1.00 | KMT2A (0.58) | KMT2ACNR2NAALAD2MMP2MMP9 | |
| SCHEMBL6249937 | 1.00 | KMT2A (0.58) | KMT2ACNR2NAALAD2MMP2MMP9 | |
| SCHEMBL6249941 | 1.00 | KMT2A (0.58) | KMT2ACNR2NAALAD2MMP2MMP9 | |
| SCHEMBL3340721 | 0.98 | KMT2A (0.57) | KMT2ACNR2NAALAD2MMP2MMP9 | |
| SCHEMBL3340707 | 0.98 | KMT2A (0.57) | KMT2ACNR2NAALAD2MMP2MMP9 | |
| SCHEMBL935547 | 0.98 | KMT2A (0.57) | KMT2ACNR2NAALAD2MMP2MMP9 | |
| Phenylacetic Acid SCHEMBL6567966 | 0.96 | KMT2A (0.54) | KMT2ACNR2NAALAD2MMP2MMP9 | |
| SCHEMBL31499163 | 0.96 | NAALAD2 (0.58) | KMT2ACNR2NAALAD2MMP2MMP9 | |
| Glycine SCHEMBL28484996 | 0.94 | KMT2A (0.53) | KMT2ACNR2NAALAD2MMP2MMP9 | |
| SCHEMBL20302075 | 0.92 | KMT2A (0.50) | KMT2ACNR2NAALAD2MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1837 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12638455-B2 | Kidney health monitoring in hypertension patients | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-05-26 | — | — | US | claimed |
| EP-3869192-B1 | METHOD FOR QUANTITATIVE DETECTION OF VARIOUS METABOLITES IN BIOLOGICAL SAMPLE | HUMAN METABOLOMICS INST INC (CN) | 2026-05-13 | — | — | EP | claimed |
| WO-2026090521-A2 | METHODS FOR DETECTING AND TREATING CAVERNOUS ANGIOMA | THE UNIVERSITY OF CHICAGO (US) | 2026-04-30 | — | — | WO | claimed |
| US-20260086089-A1 | DEVICE, METHOD AND SYSTEM FOR DIAGNOSING, MONITORING AND PREDICTING CHRONIC HEALTH CONDITIONS THROUGH URINE BIOMARKERS | HERSTASIS HEALTH FOUND (CA) | 2026-03-26 | — | — | US | claimed |
| US-12566161-B2 | Methods and consumer products for detecting a metabolite | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2026-03-03 | — | — | US | claimed |
| US-12560617-B2 | Method of diagnosing and treatment monitoring of crohn's disease and ulcerative colitis | MCMASTER UNIVERSITY (CA) | 2026-02-24 | — | — | US | claimed |
| US-20250387362-A1 | COMPOSITIONS FOR AND METHODS OF PRECISION CANCER TREATMENT | BURZYNSKI STANISLAW R (US) | 2025-12-25 | — | — | US | claimed |
| US-20250341515-A1 | METABOLOMIC BIOMARKERS FOR ACUTE KIDNEY INJURY, ASSAYS, COMPOSITIONS AND METHODS OF USE THEREOF | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2025-11-06 | — | — | US | claimed |
| US-20250290891-A1 | SYSTEMS AND METHODS FOR POINT-OF-CARE ELECTROCHEMICAL DETECTION OF BIOMARKERS IN LIQUIDS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2025-09-18 | — | — | US | claimed |
| EP-4591063-A1 | DEVICE, METHOD AND SYSTEM FOR DIAGNOSING, MONITORING AND PREDICTING CHRONIC HEALTH CONDITIONS THROUGH URINE BIOMARKERS | Herstasis Health Foundation (CA) | 2025-07-30 | — | — | EP | claimed |
| WO-1993024123-A1 | METHODS FOR TREATING VIRAL INFECTIONS | BURZYNSKI STANISLAW R (US) | 1993-12-09 | — | — | WO | claimed |
| US-5254587-A | Methods for treating AIDS | BURZYNSKI STANISLAW R (US) | 1993-10-19 | — | — | US | claimed |
| US-5244922-A | Methods for treating viral infections | BURZYNSKI STANISLAW R (US) | 1993-09-14 | — | — | US | claimed |
| EP-0500905-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN TREATING AIDS. | BURZYNSKI STANISLAW R (US) | 1992-09-02 | — | — | EP | claimed |
| US-5100807-A | Fluorescence polarization immunoassay | ABBOTT LABORATORIES (US) | 1992-03-31 | — | — | US | claimed |
| WO-1992004027-A1 | PHARMACEUTICAL COMPOSITIONS FOR USE IN TREATING AIDS | BURZYNSKI STANISLAW R (US) | 1992-03-19 | — | — | WO | claimed |
| EP-0312898-A2 | Phenylacetylglutamine (pag) analytical test | ABBOTT LABORATORIES (US) | 1989-04-26 | — | — | EP | claimed |
| EP-0069232-B1 | PHARMACEUTICAL COMPOSITION COMPRISING PHENYL ACETYL GLUTAMINE,A COMBINATION OF THIS COMPOUND WITH PHENYLACETIC ACID OR 3-(PHENYLACETYLAMINO)PIPERIDINE-2,6-DIONE,A PROCESS FOR ISOLATING THE LATTER FROM URINE AND A PROCESS FOR THE SYNTHESIS OF 3-(PHENYLACETYLAMINO)PIPERIDINE-2,6-DIONE | BURZYNSKI, Stanislaw R. (US) | 1986-10-29 | — | — | EP | claimed |
| EP-0069232-A2 | Pharmaceutical composition comprising phenyl acetyl glutamine,a combination of this compound with phenylacetic acid or 3-(phenylacetylamino)piperidine-2,6-dione,a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylamino)piperidine-2,6-dione | BURZYNSKI, Stanislaw R. (US) | 1983-01-12 | — | — | EP | claimed |
| US-4284647-A | ADMINISTERING BENZOIC OR PHENYLACETIC ACID | THE JOHNS HOPKINS UNIVERSITY (US) | 1981-08-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260086089-A1 | DEVICE, METHOD AND SYSTEM FOR DIAGNOSING, MONITORING AND PREDICTING CHRONIC HEALTH CONDITIONS THROUGH URINE BIOMARKERS | SHBG, TPO, BRCA1 | KMT2A 3894/4885CNR2 628/4885NAALAD2 3615/4885 |
| US-20250387362-A1 | COMPOSITIONS FOR AND METHODS OF PRECISION CANCER TREATMENT | SLC25A1, GOT2, FOLH1 | KMT2A 942/4885CNR2 3945/4885NAALAD2 729/4885 |
| US-12566161-B2 | Methods and consumer products for detecting a metabolite | SLC6A6, SLC7A11, CTH | KMT2A 3082/4885CNR2 2980/4885NAALAD2 383/4885 |
| US-12560617-B2 | Method of diagnosing and treatment monitoring of crohn's disease and ulcerative colitis | AADAT, GNMT, HNMT | KMT2A 899/4885CNR2 892/4885NAALAD2 453/4885 |
| US-12638455-B2 | Kidney health monitoring in hypertension patients | CHI3L1, CHI3L2, CHIT1 | KMT2A 3165/4885CNR2 2924/4885NAALAD2 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.